OBJECTIVES: Prostate cancer is the most frequent non skin cancer in men in west European countries. The first line treatment in metastatic prostate cancer is hormonal therapy, however in 18-24 months it slowly turns over into metastatic hormone resistant prostate cancer (mHRPC). The aim of this analysis was to characterize the economic value of cabazitaxel in second line treatment of mHRPC.   METHODS: A benchmarking analysis was performed, comparing cabazitaxel with other chemotherapeutic regimes used in second line treatment in Europe. As comparators we used drugs registered between 1.1.2004–18.1.2011 by EMA (according European public assessment report EPAR) for second line treatment of oncologic diseases.  Generic products (as for example docetaxel, topotekan, talidomid, temezolomid) were not taken into account. As outcome data we used the information about overall survival from the last analysis, if it was possible intention to treat was used.  These data was gathered from EPAR and Summary product characteristic and given into context with market prices, what allowed direct analysis of costs and outcomes. The total costs for therapy were counted according the median of therapy duration, dosing and price per milligram.  As example we used prices in Spain.  RESULTS: Together 25 substances were detected, in between them orphan medical products as well. Cabazitaxel demonstrated  the second best benefit in overall survival (cetuximab over the best supportive care HR=0.51 [0.41- 0.75, p<0.0001, cabazitaxel over mitoxantrone HR= 0.7 [0.59-0.83] p<0.0001). According the price cabazitaxel reached the sixth rank.  The price for one vial was 3833 euro and the price for one patient was 22 998 euro. CONCLUSIONS: The price versus overall survival hazard ratio comparison detected cabazitaxel as the second substance, mostly reducing risk of death and thus with costs which are comparable with other second line treatments in oncology.